Ricevi le ultime notizie sulle azioni NexImmune con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NEXI

Ultime notizie per

NexImmune

NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

NexImmune Inc

Nexi SpA

NEXITY A SHS by Nexity

NEXIEN BIOPHARMA INC by Nexien BioPharma, Inc.

Nexien BioPharma Inc

NEXITY FINANCIAL CORP by Nexity Financial Corp.

Comments

NexImmune Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO